Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

✍ Scribed by Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jorgensen; Peter T. Dawes; Charlotte Wiell; Daniel J. Wallace; Søren C. Tamer; Helle Kastberg; Jørgen Petersen; Stanislaw Sierakowski

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 345 KB
• Volume: 62
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.27524